Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apaziquone - Spectrum Pharmaceuticals

Drug Profile

Apaziquone - Spectrum Pharmaceuticals

Alternative Names: EO 9; EOquin; Neoquin; NOR 701; NSC 382459; Qapzola

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spectrum Pharmaceuticals
  • Developer Handok Inc; Nippon Kayaku; Spectrum Pharmaceuticals
  • Class Aziridines; Cytostatic antibiotics; Indolequinones
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bladder cancer
  • Phase I/II Leucoplakia

Most Recent Events

  • 20 Aug 2019 Spectrum Oncology terminates phase I/II trial in Leucoplakia in India, before August 2019 (Topical) (CTRI2017-08-009275)
  • 01 Jul 2019 No development reported - Preregistration for Bladder cancer (Adjuvant therapy) in USA (Intravesicular)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top